

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the draft scope consultation, one consultee noted that erlotinib and gefitinib are used more frequently in people of south or east Asian ethnicity and in women.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The issue of more frequent use of erlotinib and gefitinib in people of south or east Asian ethnicity and in women is not an equalities issue that can be addressed within a NICE technology appraisal. Uptake of the guidance is not part of the Committee's considerations. Any positive recommendations would carry a mandatory funding directive and should be made available where clinically relevant regardless of ethnicity.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): Frances Sutcliffe

Date: 19 02 2013